Thomas Brannagan, MD
Neurology · New York, NYNPI 1245327337
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Akcea Therapeutics, Inc. at 27.5% of the total. Reporting peaked in 2019 at $65,920 and has fallen 67.7% since, to $21,281 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $448.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akcea Therapeutics, Inc.$41K
- CSL Behring$23K
- Alnylam Pharmaceuticals Inc.$20K
- Sanofi$17K
- Grifols USA, LLC$16K
- AstraZeneca$16K
- plus $15K from 20 others
Across 188 payments — averaging $5470.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$386K
- Vertex$160K
- Sanofi US Services Inc.$100K
- Grifols Biologicals LLC$74K
- H. Lundbeck A S$69K
- Argenx US, Inc.$54K
- plus $186K from 7 others
What the payments were for
- Consulting fees$44,92430%
- Speaking & faculty fees$57,54539%
- Travel & lodging$34,43723%
- Food & beverage$11,8548%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akcea Therapeutics, Inc. | 41 | $40,908 |
| CSL Behring | 33 | $23,473 |
| Alnylam Pharmaceuticals Inc. | 65 | $19,702 |
| Sanofi | 16 | $17,096 |
| Grifols USA, LLC | 35 | $16,323 |
| AstraZeneca(2 entities) | 43 | $16,039 |
| Pfizer | 7 | $6,325 |
| Argenx US, Inc. | 13 | $3,293 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $1,944 |
| UCB SA | 9 | $1,445 |
| EDW Pharma, Inc. | 1 | $493 |
| Grifols Shared Services North America, Inc. | 3 | $481 |
| Supernus Pharmaceuticals, Inc. | 5 | $217 |
| EMD Serono, Inc. | 8 | $214 |
| Novartis | 12 | $190 |
| Teva Pharmaceuticals USA, Inc. | 5 | $181 |
| Catalyst Pharmaceuticals, Inc. | 5 | $130 |
| Bard Peripheral Vascular, Inc. | 3 | $98 |
| Johnson & Johnson | 1 | $43 |
| ITF Therapeutics LLC | 1 | $34 |
| Strongbridge US Inc. | 2 | $29 |
| Lundbeck LLC | 2 | $29 |
| Eisai Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$148,772 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmvuttraVutrisiran Sodium | 17 | $2,006,900 |
| WainuaEplontersen Sodium | 31 | $1,322,222 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 79 | $1,304,803 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 106 | $1,296,698 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 142 | $1,237,329 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 77 | $1,018,526 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 26 | $968,237 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 50 | $422,241 |
| VimpatLacosamide | 11 | $11,821 |
| Pregabalin | 179 | $4,570 |
| Epinephrine | 15 | $4,409 |
| Oxcarbazepine | 68 | $2,799 |
| Gabapentin | 108 | $2,564 |
| Lamotrigine | 75 | $2,001 |
| Duloxetine Hcl | 47 | $1,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alnylam Pharmaceuticals Inc.Amvuttra | $19,702 | $2,006,90017 claims |
| AstraZenecaWainua | $16,039 | $1,322,22231 claims |
| PfizerOctagam | $6,325 | $1,296,698106 claims |
| Grifols USA, LLCGamunex-C | $16,323 | $1,237,329142 claims |
| CSL BehringPrivigen | $23,473 | $1,018,52677 claims |
| Argenx US, Inc.Vyvgart Hytrulo | $3,293 | $968,23726 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,944 | $422,24150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.